DR. MATTHEW JOHN DURING, M.D., PH.D.
Medical Practice at Front St, Columbus, OH
License number
Ohio MD069648L
Category
Medical Practice
Type
Neurological Surgery
Address
Address
425 N Front St APT 722, Columbus, OH 43215
Phone
(917) 727-7050
Professional information
Glutamic Acid Decarboxylase (Gad) Based Delivery System
US Patent:
7955595, Jun 7, 2011
Filed:
Jan 11, 2010
Appl. No.:
12/685385
Inventors:
Matthew During - Columbus OH, US
Michael Kaplitt - New York NY, US
Michael Kaplitt - New York NY, US
Assignee:
Neurologix, Inc. - Fort Lee NJ
International Classification:
A01N 63/00, A01N 65/00, A61K 48/00, C12N 15/00
US Classification:
424 932, 424 931, 4353201
Abstract:
The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.
Methods And Compositions For The "Browning" Of White Fat
US Patent:
2014005, Feb 27, 2014
Filed:
Aug 21, 2013
Appl. No.:
13/971968
Inventors:
Matthew During - Columbus OH, US
Lei Cao - Columbus OH, US
Lei Cao - Columbus OH, US
International Classification:
A61K 38/18, A61K 31/353, A61K 31/24, A61K 31/135, A61K 31/138, A61K 31/7088, A61K 31/4045
US Classification:
514 48, 514 44 R, 514456, 514419, 514654, 514653, 514510
Abstract:
Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become brown adipose tissue in a subject include the administration of one or more agents. The agent can increase or induce hypothalamic expression of BDNF, can be a TrkB receptor agonist or a beta-3 adrenergic receptor agonist, or encode an agonist that modulates a hypothalamic-adipocyte axis.
Treatment Of Metabolic-Related Disorders Using Hypothalamic Gene Transfer Of Bdnf And Compositions Therefor
US Patent:
2011028, Nov 24, 2011
Filed:
Mar 27, 2009
Appl. No.:
12/934735
Inventors:
Matthew J. During - Columbus OH, US
Lei Cao - Columbus OH, US
Lei Cao - Columbus OH, US
Assignee:
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH
International Classification:
A61K 48/00, C12N 15/85, C12N 15/86, A61P 3/08, A61P 3/00, A61P 3/10, A61P 3/04, C12N 15/63, C12N 15/861
US Classification:
514 44 R, 4353201, 435455
Abstract:
Described herein is a system which uses a gene therapy particle that includes at least one gene, cDNA, fragment or analogue of at least one neurotropin that binds to the trkB receptor or the trkB receptor itself. The gene therapy particle is capable of being delivered to a subject in need thereof for therapy of a metabolic disorder. In a particular aspect, this invention is directed to an inventive method that demonstrates a remarkable efficacy on lowering body weight.
Glutamic Acid Decarboxylase (Gad) Based Delivery System
US Patent:
2011020, Aug 25, 2011
Filed:
Apr 27, 2011
Appl. No.:
13/095273
Inventors:
Matthew During - Columbus OH, US
Michael Kaplitt - New York NY, US
Michael Kaplitt - New York NY, US
Assignee:
NEUROLOGIX, INC. - Fort Lee NJ
International Classification:
A61K 31/7088, A61P 25/28
US Classification:
514 44 R
Abstract:
The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.
System For Modulating Expression Of Hypothalmic Brain-Derived Neurotrophic Factor (Bdnf)
US Patent:
2011027, Nov 10, 2011
Filed:
Oct 29, 2009
Appl. No.:
13/126026
Inventors:
Matthew J. During - Columbus OH, US
Lei Cao - Columbus OH, US
Lei Cao - Columbus OH, US
Assignee:
THE OHIO STATE UNIVERSITY - Columbus OH
International Classification:
A61K 39/00, A61K 31/7088, C12N 15/63, A61K 38/18, A61P 3/00, A61P 35/00, A61P 3/04, A61P 3/10, A61P 37/04, A61P 25/00, A61K 48/00, C07H 21/02
US Classification:
4241981, 514 44 R, 514 44 A, 4353201, 514 83, 536 245
Abstract:
Methods for treating tumor associated diseases by administering a nucleic acid sequence encoding brain derived neurotrophic factor (BDNF) where the expression reduces the symptoms of the disease and compositions for mediation of enrichment-induced tumor resistance having brain derived neurotrophic factor (BDNF) are disclosed.
Compositions And Methods For Skin Care
US Patent:
2010022, Sep 2, 2010
Filed:
Jul 17, 2008
Appl. No.:
12/669246
Inventors:
Matthew J. During - Columbus OH, US
Assignee:
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH
International Classification:
A61K 8/64, A61Q 17/04, A61Q 19/00
US Classification:
424 59, 514 16
Abstract:
The present disclosure contemplates compositions and methods for skin care. In some embodiments, the compositions may comprise delta opioid receptor agonists. The skin care composition may comprise peptide delta opioid receptor agonists, non-peptide delta opioid receptor agonists, or combinations thereof. In further embodiments, the peptide delta opioid receptor agonists may be chosen from enkephalins and/or deltorphins. In yet other embodiments, the delta opioid receptor agonists may be conjugated to another molecule. For example, the delta opioid receptor agonist may be conjugated to a lipid in order to facilitate entry across the stratum corneum. Further disclosed herein is the cosmetic use of at least one combination as described above, in a composition suitable for topical application to the skin, as an agent for smoothing out wrinkles and fine lines, such as expression wrinkles.
Methods And Compositions For The Treatment Of Neurological Disease
US Patent:
2010016, Jul 1, 2010
Filed:
Mar 1, 2010
Appl. No.:
12/714613
Inventors:
Matthew J. During - Columbus OH, US
Annamaria Vezzani - Milan, IT
Annamaria Vezzani - Milan, IT
Assignee:
NEUROLOGIX, INC. - Fort Lee NJ
International Classification:
A61K 31/7088, C12N 5/02, C12N 5/071, C12N 15/63
US Classification:
514 44 R, 435375, 435368, 4353201
Abstract:
The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit for subjects afflicted with a neurological disorder.
High Transgene Expression Of A Pseudotyped Adeno-Associated Virus Type
US Patent:
2010009, Apr 15, 2010
Filed:
Nov 18, 2009
Appl. No.:
12/620785
Inventors:
Yuhong Liu - Cherry Hill NJ, US
Jia Luo - Philadelphia PA, US
Matthew During - Columbus OH, US
Jia Luo - Philadelphia PA, US
Matthew During - Columbus OH, US
Assignee:
NEUROLOGIX, INC. - Fort Lee NJ
International Classification:
C12N 7/01
US Classification:
4352351
Abstract:
The present invention related to methods and compositions comprising recombinant vectors comprising chimeric capsids and recombinant pseudotyped vectors with non-native capsid protein(s). The recombinant vectors of the invention confer an altered tropism that permits selective targeting of desired cells.